Get the Stockscreener App
3.13
2.89%
0.06
Quantum Biopharma Ltd stock is traded at $3.13, with a volume of 39,365.
It is up +2.89% in the last 24 hours and up +6.35% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$3.07
Open:
$3.08
24h Volume:
39,365
Relative Volume:
0.14
Market Cap:
$133
Revenue:
-
Net Income/Loss:
$-31.97M
P/E Ratio:
-0.3789
EPS:
-8.2612
Net Cash Flow:
$-5.66M
1W Performance:
-8.18%
1M Performance:
+6.35%
6M Performance:
-11.02%
1Y Performance:
-62.28%
1-Day Range:
$3.03
$3.24
1-Week Range:
$3.03
$3.58
52-Week Range:
$2.07
$14.85
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
3.17 | 144 | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
548.27 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
810.64 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,055.46 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
142.54 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
219.14 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum Biopharma Provides Corporate Update - The Manila Times
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves - TradingView
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm - Benzinga
Quantum BioPharma Stock Gains 6.7% on FDA Clearance for Lucid-MS Phase 2 Trial - kalkine.ca
Quantum BioPharma Stock Under Pressure as Regulatory Uncertainty Tests the Lucid-MS Growth Story - kalkine.ca
Quantum BioPharma Stock Slides as Bearish Momentum, Funding Risk and Biotech Volatility Pressure CN:QNTM - kalkine.ca
Quantum (QNTM) Results Breakdown: The Latest Report Adds New Financial Reference Points under the Current Snapshot; Post-Earnings Trading: The Stock Records a 9.24% Decrease on the DayGuidance Revision Trend - vinanet.vn
Quantum BioPharma Ltd. (NASDAQ: QNTM) Share Price, QNTM Stock News, QNTM Share Price & Updates - Kalkine
Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - NewMediaWire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - Benzinga
Quantum BioPharma Ltd (CN:QNTM) Gains Momentum as Clinical Breakthroughs Improve Investor Outlook - kalkine.ca
Quantum BioPharma Ltd Stock Intrinsic Values | HAM:0K91 - GuruFocus
Quantum BioPharma Ltd Stock Historical Valuations - GuruFocus
QNTM Q4 2025 Earnings: Loss of $0.71 Per Share Reported as Stock Advances 17.65%Revenue Report - Vinanet
Quantum BioPharma Ltd (HAM:0K91) Stock Earnings Transcripts - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Quantum BioPharma Ltd (HAM:0K91) Stock Today? - GuruFocus
Quantum BioPharma (HAM:0K91) ROC (Joel Greenblatt) % : -34,873.53% (As of Mar. 2026) - GuruFocus
HAM:0K91 Dividend: Does Quantum BioPharma Ltd Pay a Dividend? - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price & 30 Year Financial Data - GuruFocus
Quantum BioPharma Ltd Stock Operating Data - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Competitors 2026 - GuruFocus
Quantum BioPharma Ltd (HAM:0K91)Valuation Measures & Financial Statistics - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Valuation - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock News, Headlines & Updates - GuruFocus
Quantum BioPharma (HAM:0K91) EPS (Basic) : €-7.12 (TTM As of Mar. 2026) - GuruFocus
Quantum BioPharma (HAM:0K91) Dividend Yield % : 0.00% (As of Aug. 16, 2026) - GuruFocus
Quantum BioPharma (HAM:0K91) OCF Yield % : -22.72 (As of Aug. 16, 2026) - GuruFocus
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time - kalkine.ca
QNTM Surges 10.5%: Quantum Biopharma Gains Momentum as It Approaches Key ResistanceIV Crush Alert - Vinanet
Quantum BioPharma Stock Surges as Lucid-MS Progress and Biotech Catalysts Fuel Bullish Momentum - kalkine.ca
Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment - kalkine.ca
Quantum BioPharma Stock Faces Fresh Pressure as Biotech Risk and Funding Concerns Weigh on Sentiment - kalkine.ca
Quantum BioPharma reports Q2 results, FDA clears MS trial By Investing.com - Investing.com Nigeria
Quantum BioPharma reports Q2 results, FDA clears MS trial - Investing.com
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial - The Manila Times
Quantum BioPharma Reports Q2 2026 Results, Reduces Operating Expenses 53% and Secures FDA Clearance for Lucid-MS Phase 2 Trial - Quiver Quantitative
Quantum BioPharma Reports Q2 2026 Results as FDA Clears Lucid-MS for Phase 2 Multiple Sclerosis Trial - kalkine.ca
Quantum BioPharma (QNTM) doubles liquidity and secures FDA clearance for Lucid-MS Phase 2 - Stock Titan
Quantum BioPharma Says Cash Could Fund Plans to Oct. 2027 - Stock Titan
Quantum Biopharma (QNTM) narrows Q2 loss but leans on crypto and new debt - Stock Titan
Quantum BioPharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis - NeurologyLive
Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis - Yahoo Finance
Quantum BioPharma (QNTM) ties August 10 press release into Form F-3 - Stock Titan
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple - Benzinga
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis - Barchart.com
FDA Clears Quantum BioPharma's Lucid-MS for Phase 2 — QNTM Shares Slide Anyway - kalkine.ca
Quantum BioPharma Ltd. (CN:QNTM) Shares Decline as Clinical Development Risks and Biotech Market Volatility Pressure Investor Sentiment - kalkine.ca
Quantum Biopharma (QNTM) Earnings Date and Reports 2026 - MarketBeat
Quantum Biopharma Ltd Stock (QNTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):